Fig. 3.

DDX39B knockdown inhibits CRC growth and metastasis in vitro and in vivo. Knockdown efficiency mediated by two lentivirus-delivered DDX39B-specific shRNA (sh#1 and sh#2) was verified by qRT-PCR (a) and western blotting (b) in HCT116 and SW620 cells. The cell viability and proliferation of DDX39B-knockdown CRC cells were measured by CCK8 assays (c), colony formation assays (d), and EdU assays (e). The motility of DDX39B-knockdown CRC cells was examined by transwell migration/invasion assays (f) and wound healing assays (g). h The protein levels of ITGA5, ITGB1, pFAK^Y397, and FAK in DDX39B-knockdown CRC cells were detected by western blotting. The growth and metastatic abilities of DDX39B-knockdown CRC cells in vivo were assessed in nude mice by subcutaneous and lung metastasis tumor models (n = 8), respectively. The images (i), tumor sizes (j), tumor weights (k), and Ki-67 expression (l) of subcutaneous xenografts are presented. Representative pulmonary metastases detected by H&E staining are shown, along with the number of metastatic nodules (m). Data are presented as mean ± SD. The p values were obtained by two-way ANOVA (c, j) or one-way ANOVA (others). **p < 0.01, ***p < 0.001